Synopsis:
The mechanisms of pulmonary arterial hypertension remain uncertain, and the diagnosis of pulmonary arterial hypertension is challenging. The major advances of the diagnostic modalities and management strategies include new uses of routine biomarkers including antinuclear antibody, B-type natriuretic peptide, circulating endothelial cells and microRNA in diagnosis; and microRNA, mesenchymal stem cells and remote postconditioning for pulmonary protection in treatment. Understanding the progress in terms of the mechanisms and concepts of pulmonary hypertension implicates significant improvement of the management protocols of this disorder. In this article, the advances of the diagnostic modalities and management strategies of PAH are discussed.
